Scilex Holding Company
Officers & Directors
David Lemus Director Stephen Ma Chief Financial Officer (Principal Financial Officer) Jaisim Shah Chief Executive Officer, President and Director Chief Executive Officer and President (Principal Executive Officer) Jay Chun Director Yue Alexander Wu Director Dorman Followwill Director Henry Ji, Ph.D. Executive Chairperson and Director Stephen Ma Chief Financial Officer ,
Scilex Holding Company currently has 34 employees.
News about Scilex Holding Company Key Personnel |
Scilex Holding Company Faces Financial Strain Amid New Study on ZTlido vs. Lidocaine PatchScilex Holding Company Announces Pain Medicine Study and Financial Challenges Palo Alto, CA – January 13, 2025 – Scilex Holding Company (Nasdaq: SCLX), a company dedicated to the development and commercialization of non-opioid pain management therapies, finds itself at a crucial juncture as it contends with severe financial losses alongside a significant study on its pain management product, ZTlido. This retrospective claims data analysis, recently published in Pain Medicine News, compares the effectiveness of ZTlido to the widely used lidocaine 5% patch, offering a critical look at the competitive landscape for pa...
|
PALO ALTO, Calif. Sept. 18, 2024 – Scilex Holding Company (Nasdaq: SCLX), an innovative revenue-generating organization dedicated to acquiring, developing, and commercializing non-opioid pain management products, recently made significant strides in the healthcare sector as outlined in its latest press release. These advancements include the continued partnership with Endeavor Distribution LLC to enhance commercial product offerings and the successful repayment of a $10 million loan from FSF 33433 LLC.Despite these promising developments, not all recent news has been favorable for Scilex. Following the announcement, the company’s stock witnessed a decline of 12%. Furthermore, the company’s financial st...
|
Introduction
Scilex Holding Company, a revenue-generating company dedicated to non-opioid pain management, has announced the appointment of Dr. Annu Navani to its Board of Directors. This move highlights the company s commitment to enhancing its capabilities in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. With previous financial challenges and a recent notice to lenders regarding short positions on restricted shares, it is crucial to delve into the facts and assess their impact on Scilex Holding Company s future.
Scilex Holding Company s Financial Performance
During the 12 months ending in the third quarter of 2023, Scilex Holding Company reported a cumul...
|
Scilex Holding Company, a leading player in non-opioid pain management products, recently achieved a significant milestone in its operations. The company announced the successful completion of a Good Manufacturing Practices (GMP) inspection conducted by the U.S. Food and Drug Administration (FDA) for the enhanced manufacturing facility of ZTlido in Japan. This accomplishment reaffirms Scilex s commitment to delivering high-quality pain management products for acute and chronic pain treatment.
The inspection specifically focused on the manufacturing facility of Oishi Koseido Co., Ltd., located in Tosu, Saga, Japan. Oishi is responsible for producing ZTlido, a non-opioid pain management product, ...
|
|
|
